Tesamorelin
Tesamorelin dosing, mechanism of action, side effects, and visceral fat reduction. FDA-approved Egrifta clinical reference.
Growth HormoneSubcutaneous injection2mg daily
Overview
Tesamorelin is a synthetic GHRH analog FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy (Egrifta).
Mechanism of Action
- GHRH receptor agonism — Stimulates pituitary GH release
- Visceral fat reduction — Specifically targets abdominal/visceral adipose tissue
- IGF-1 elevation — Increases insulin-like growth factor 1
- Lipid improvement — Reduces triglycerides
Dosing
2mg subcutaneously once daily. FDA-approved dosing for lipodystrophy.
Safety
FDA-approved with extensive clinical data. Monitor glucose and IGF-1 levels.
Last updated: 2026-03-27